The Nomination Committee proposes that Fredrik Lindberg is elected to the Board of Directors

Regulatory information
Enzymatica’s Nomination Committee proposes to the Annual General Meeting on May 5, 2020 that Bengt Baron, Marianne Dicander Alexandersson, Guðmundur Pálmason, Mats Andersson and Louise Nicolin are re-elected, and that Fredrik Lindberg, the company’s present CEO, will replace Sigurgeir Guðlaugsson, who will not be seeking re-election.

As announced earlier, Fredrik Lindberg will leave the company at summer after having accepted a job offer from a private pharmaceutical company that does not compete with Enzymatica.

  • “We are very pleased that Fredrik is at disposal to be elected to the Board of Directors. Since Fredrik has a long experience and knowledge of Enzymatica, and possesses great medical expertise, it is most valuable that he can continue to work for the company,” says Håkan Roos, Chairman of the Nomination Committee, and continues:
  • “We would also like to thank Sigurgeir Guðlaugsson for his strong contributions to the Board of Directors with his international experience from life science companies and a strong network.”

Fredrik Lindberg has been CEO and Chief Medical Officer for Enzymatica since 2015. Before that he was CEO and Chief Scientific Officer for the listed medtech company BoneSupport. He has also been Medical Director Nordic Area for the American company Searle  Pharmaceuticals. Fredrik is an MD, PhD and Associate Professor in Clinical Pharmacology, and was head at the Department of Clinical Pharmacology at Lund University Hospital.

For more information, please contact:

Bengt Baron, Chairman, Enzymatica AB
Phone: +46 (0)708-59 30 09 | Email: bengt.baron@outlook.com

Fredrik Lindberg, CEO Enzymatica AB
Phone: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com

Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: +46 (0)701-88 50 21 | Email: carl-johan.wachtmeister@enzymatica.com

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about ten markets. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com  and www.enzymatica.se/en/section/media/press-releases/

Enzymatica’s certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: certifiedadviser@penser.se

Enzymatica AB Ideon Science Park, SE-223 70 Lund, Sweden Telefon +46 46-286 31 00

Documents

Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.